Akeso Initiates Phase II Study of Novel Bispecific ADC for Advanced NSCLC
Akeso has announced the first patient has been dosed in a Phase II clinical trial of its innovative TROP2/Nectin-4 bispecific antibody-drug conjugate, AK146D1, in combination with Ivonescimab for treating advanced non-small cell lung cancer (NSCLC). This promising development highlights the potential of targeted therapies in oncology and the ongoing commitment to improving patient outcomes in cancer treatment.